QLS-101
- Generic Name
- QLS-101
A Study to Evaluate Safety and Tolerability of QLS-101 in NTG
Phase 2
Completed
- Conditions
- Normal Tension Glaucoma (NTG)
- Interventions
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Qlaris Bio, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT04857827
- Locations
- 🇺🇸
Vance Thompson Vision, Sioux Falls, South Dakota, United States
Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).
Phase 2
Completed
- Conditions
- Ocular HypertensionPrimary Open Angle Glaucoma
- Interventions
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Qlaris Bio, Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT04830397
- Locations
- 🇺🇸
Dixon Eye Care, Albany, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath